Outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface dissemination from ovarian neoplasms
about
Cytoreductive surgery (SRC) and hyperthermic intraperitoneal chemotherapy (HIPEC) for treatment of peritoneal carcinomatosis: Our initial experience and technical details.Intraperitoneal chemotherapy in ovarian cancer: a review of tolerance and efficacy.Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis.The role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer: A Review.Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy to Treat Advanced/Recurrent Epithelial Ovarian Cancer: Results from a Retrospective Study on Prospectively Established DatabaseRepeat cytoreductive surgery and heated intraperitoneal chemotherapy may offer survival benefit for intraperitoneal mesothelioma: a single institution experience.Intraperitoneal chemotherapy from Armstrong to HIPEC: challenges and promise.Outcomes with cytoreductive surgery and HIPEC for peritoneal metastasis.Hyperthermic Intraperitoneal Chemotherapy after Secondary Cytoreduction in Epithelial Ovarian Cancer: A Single-center Comparative Analysis.Docetaxel combined with intraperitoneal hyperthermic perfusion chemotherapy and hyperthermia in the treatment of advanced ovarian cancerAssessing the impact of perioperative blood transfusions on the survival of adults undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for appendiceal carcinomatosis.Different sequential approaches of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in treating ovarian cancer with malignant ascites.Increased Plasma Levels of Danger-Associated Molecular Patterns Are Associated With Immune Suppression and Postoperative Infections in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
P2860
Q36160064-84D87EF2-F6A5-499E-B645-404A5F5E22FFQ36444374-78A30127-174B-4F06-834D-CF4A8FC1BE09Q36611761-B8FB191E-723F-4597-BA63-6A31635DBE9EQ36758929-FA96DC0F-69F9-4841-9930-AEB745B1928CQ36804710-7C1E1560-CDC4-4571-A750-397850A041AFQ38155428-E5AF52FB-968C-4A3C-B099-22AFA13F6CD1Q38171356-90FB68F0-6DA0-4A4A-94AC-938AD430F852Q38244051-B2687338-0E9F-42E3-86CD-ADF35F3A11ABQ40251231-B773D1A4-EF43-40E7-B336-2CF8A0463C8DQ40490536-0E10B5B8-DF00-4EC0-8BE7-A21ABA51EDE7Q48163771-39AFB399-E6F3-4792-BF4D-797AF9E5FA9BQ51139020-20DD133B-B265-4AF8-9B75-A4D8257FFD99Q55044603-5D2E8B74-C98F-4210-A400-9BFA84C9739F
P2860
Outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface dissemination from ovarian neoplasms
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 April 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Outcomes after cytoreductive s ...... ination from ovarian neoplasms
@en
Outcomes after cytoreductive s ...... nation from ovarian neoplasms.
@nl
type
label
Outcomes after cytoreductive s ...... ination from ovarian neoplasms
@en
Outcomes after cytoreductive s ...... nation from ovarian neoplasms.
@nl
prefLabel
Outcomes after cytoreductive s ...... ination from ovarian neoplasms
@en
Outcomes after cytoreductive s ...... nation from ovarian neoplasms.
@nl
P2093
P2860
P1476
Outcomes after cytoreductive s ...... ination from ovarian neoplasms
@en
P2093
E Nicole Parson
Edward A Levine
Greg Russell
John H Stewart
Perry Shen
Samuel Lentz
P2860
P304
P356
10.1016/J.AMJSURG.2011.02.004
P407
P577
2011-04-07T00:00:00Z